Baillie Gifford Amends Recursion Pharma Stake (SC 13G/A)
Ticker: RXRX · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, biotechnology, investor-update
TL;DR
**Baillie Gifford updated their Recursion Pharma holdings; keep an eye on institutional sentiment.**
AI Summary
Baillie Gifford & Co, a major investment management firm, filed an amendment (SC 13G/A) on January 26, 2024, indicating a change in their ownership of Recursion Pharmaceuticals, Inc. Class A Common Stock as of December 29, 2023. This filing, an amendment number 3, shows that Baillie Gifford continues to be a significant institutional holder, which can signal confidence in the company's long-term prospects. For investors, this matters because large institutional holdings can provide stability and a vote of confidence, but any future reductions could also impact stock price.
Why It Matters
This filing updates Baillie Gifford's ownership position in Recursion Pharmaceuticals, providing transparency on a major institutional investor's stake, which can influence market perception and trading activity.
Risk Assessment
Risk Level: low — This is a routine amendment filing by an institutional investor, indicating a change in their ownership percentage, which is generally a low-risk event.
Analyst Insight
Investors should monitor future SC 13G/A filings from Baillie Gifford & Co to track their evolving stake in Recursion Pharmaceuticals, as significant changes could signal shifts in institutional confidence.
Key Players & Entities
- Baillie Gifford & Co (company) — the institutional investor filing the SC 13G/A
- RECURSION PHARMACEUTICALS, INC. (company) — the subject company whose shares are being reported
- December 29, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the date the SC 13G/A was filed
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, specifically Amendment No. 3 for Recursion Pharmaceuticals, Inc.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BAILLIE GIFFORD & CO, an investment management firm based in Edinburgh, X0 (Scotland).
What is the subject company of this filing?
The subject company is RECURSION PHARMACEUTICALS, INC., a company in the biological products industry (SIC 2836) with its business address at 41S Rio Grande Street, Salt Lake City, UT 84101.
What is the specific class of securities reported in this filing?
The specific class of securities reported is Class A Common Stock of RECURSION PHARMACEUTICALS, INC., with CUSIP Number 75629V104.
When was the event that triggered this filing?
The date of the event which required the filing of this statement was December 29, 2023.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding RECURSION PHARMACEUTICALS, INC. (RXRX).